4 research outputs found
Modes of action of rosemary and Debaryomyces hansenii against Aspergillus westerdijkiae in dry-cured meat matrix
Aspergillus westerdijkiae is an ochratoxin A (OTA) producer mould in dry-cured meat products. Natural strategies
to control ochratoxigenic moulds using biocontrol agents (BCAs) are currently in the spotlight. The aim of this
study was to test the potential antiochratoxigenic activity of rosemary leaves (R), rosemary essential oil (REO) and
Debaryomyces hansenii FHSCC 253H (Dh) as BCAs against A. westerdijkiae in a dry-cured fermented sausage-based
medium. The mechanisms involved in their effect were also analysed by Proteomics, using a Q-Exactive Plus. Three
batches were carried out: a control without BCAs, another one with R+REO and one with Dh. R (2 g/kg) and Dh (100
μL of 10^6 cells/mL) were added to the medium and REO was added on the casing, which was put onto the medium
surface to simulate the real product. Significant OTA reductions of 73.87 % and 88.26 % were provoked by R+REO
and Dh, respectively. Proteomics revealed that the BCAs affected to proteins linked to OTA biosynthesis and the
cell wall integrity pathway (CWI). Proteins from PKS ER domain, directly involved in mycotoxin biosynthesis, were
diminished in abundance by both treatments (R+REO or Dh). R+REO altered the CWI by decreasing proteins related
to the synthesis of cell surface polysaccharides and actin assembly, and increasing the cell wall protein PhiA, involved
in conidiogenesis. Dh decreased the NRPS protein, indispensable for the formation of the OTB, an OTA precursor,
and affected to the CWI by lowering the abundance of proteins associated with the actin binding, the synthesis of
polysaccharides and the response against cell wall stress agents. Therefore, rosemary and D. hansenii FHSCC 253H
are potentially useful to minimise the hazard posed by A. westerdijkiae in dry-cured fermented sausages within a
HAPPCC framework.This research was funded by Foundation for Science and Technology (FCT/MCTES to CIMO, UIDB/00690/2020). Fondo
Europeo de Desarrollo Regional-“Una manera de hacer Europa” (GR18056). Grant PID2019-104260GB-I00 funded
by MCIN/AEI/ 10.13039/501100011033. Grant BES-2017-081340 funded by MCIN/AEI/ 10.13039/501100011033
and by “ESF Investing in your future”. Grant UNEX-AE-3394 funded by MCIN/AEI/ 10.13039/501100011033 and by
“ERDF A way of making Europe”. Date of PhD graduation: 14/12/2021info:eu-repo/semantics/publishedVersio
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
© 2024 Ferrata Storti Foundation Published under a CC BY-NC license.Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.This study was partially supported by the Jazz Pharmaceuticals and Cooperative Research Thematic Network (RTICC) grant RD12/0036/014 (ISCIII & ERDF).Peer reviewe
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia : a PETHEMA registry study
This study was supported in part by the Jazz Pharmaceuticals and Cooperative Research Thematic Network (RTICC) grant RD12/0036/014 (ISCIII and ERDF)